U.S. FDA Grants Reunion Neuroscience’s Luvesilocin (RE104) Breakthrough Therapy Designation Status

hastingstribune · · 1 min read

Clinically Reviewed by Editorial Advisory Panel
anxiety
U.S. FDA Grants Reunion Neuroscience’s Luvesilocin (RE104) Breakthrough Therapy Designation Status

U.S. FDA Grants Reunion Neuroscience’s Luvesilocin (RE104) Breakthrough Therapy Designation Status

Originally reported by hastingstribune. Read more

Source: https://www.hastingstribune.com/ap/business/u-s-fda-grants-reunion-neuroscience-s-luvesilocin-re104-breakthrough-therapy-designation-status/article_5b114c3c-802f-52d2-a194-d78b06cfa09e.html